Center for Abdominal Core Health, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
United States Food and Drug Administration, Silver Spring, MD, USA.
Hernia. 2024 Aug;28(4):1137-1144. doi: 10.1007/s10029-024-02990-5. Epub 2024 Apr 29.
The study objective is to document value created by real-world evidence from the Abdominal Core Health Quality Collaborative (ACHQC) for regulatory decisions. The ACHQC is a national effort that generates data on hernia repair techniques and devices.
Two retrospective cohort evaluations compared cost and time of ACHQC analyses to traditional postmarket studies. The first analysis was based on 25 reports submitted to the European Medicines Agency of 20 mesh products for post-market surveillance. A second analysis supported label expansion submitted to the Food and Drug Administration, Center for Devices and Radiological Health for a robotic-assisted surgery device to include ventral hernia repair. Estimated costs of counterfactual studies, defined as studies that might have been done if the registry had not been available, were derived from a model described in the literature. Return on investment, percentage of cost savings, and time savings were calculated.
45,010 patients contributed to the two analyses. The cost and time differences between individual 25 ACHQC analyses (41,112 patients) and traditional studies ranged from $1.3 to $2.2 million and from 3 to 4.8 years, both favoring use of the ACHQC. In the second label expansion analysis (3,898 patients), the estimated return on investment ranged from 11 to 461% with time savings of 5.1 years favoring use of the ACHQC.
Compared to traditional postmarket studies, use of ACHQC data can result in cost and time savings when used for appropriate regulatory decisions in light of key assumptions.
本研究旨在记录来自腹部核心健康质量协作(ACHQC)的真实世界证据在监管决策方面创造的价值。ACHQC 是一项生成疝修补技术和器械数据的全国性工作。
两项回顾性队列评估将 ACHQC 分析的成本和时间与传统的上市后研究进行了比较。第一项分析基于向欧洲药品管理局提交的 20 项 20 目网产品的上市后监测报告。第二项分析支持向美国食品和药物管理局设备和放射卫生中心提交的标签扩展申请,该申请涉及一种机器人辅助手术设备,将腹疝修补术纳入其中。假设没有登记处,可能进行的对照研究的估计成本是从文献中描述的模型中得出的。投资回报率、成本节约百分比和节省的时间都进行了计算。
两项分析共纳入 45010 名患者。25 项 ACHQC 分析(41112 名患者)和传统研究之间的单个分析的成本和时间差异从 130 万美元到 2200 万美元不等,时间从 3 年到 4.8 年不等,两者都倾向于使用 ACHQC。在第二次标签扩展分析(3898 名患者)中,使用 ACHQC 的投资回报率估计范围为 11%至 461%,节省时间为 5.1 年。
根据关键假设,在适当的监管决策中使用 ACHQC 数据可以节省成本和时间,与传统的上市后研究相比。